Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO) issued its earnings results on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.05, FiscalAI reports.

Lexeo Therapeutics Trading Up 8.9%

Shares of LXEO stock opened at $5.74 on Wednesday. Lexeo Therapeutics has a 12-month low of $1.45 and a 12-month high of $10.99. The stock has a market capitalization of $418.96 million, a P/E ratio of -2.62 and a beta of 1.78. The firm’s 50 day moving average is $6.69 and its 200 day moving average is $7.97.

Insiders Place Their Bets

In other news, CEO Richard Nolan Townsend sold 10,173 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $6.38, for a total transaction of $64,903.74. Following the transaction, the chief executive officer directly owned 392,483 shares of the company’s stock, valued at $2,504,041.54. This represents a 2.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds have recently bought and sold shares of LXEO. Bank of America Corp DE lifted its holdings in Lexeo Therapeutics by 6.1% in the third quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock valued at $188,000 after acquiring an additional 1,626 shares during the period. California State Teachers Retirement System increased its stake in shares of Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after purchasing an additional 2,148 shares in the last quarter. Intech Investment Management LLC raised its stake in shares of Lexeo Therapeutics by 19.5% in the fourth quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock worth $141,000 after buying an additional 2,317 shares during the period. Susquehanna Portfolio Strategies LLC lifted its holdings in Lexeo Therapeutics by 14.4% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 26,205 shares of the company’s stock valued at $260,000 after purchasing an additional 3,296 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Lexeo Therapeutics by 160.2% during the 4th quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company’s stock valued at $58,000 after buying an additional 3,615 shares in the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LXEO shares. HC Wainwright decreased their price objective on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. Chardan Capital reissued a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, January 13th. Raymond James Financial initiated coverage on Lexeo Therapeutics in a research note on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 price target for the company. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.88.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.